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Abstract 
Infectious diseases kill over 17 million people a year, among which bacterial infections stand out. From all the bacte‑
rial infections, tuberculosis, diarrhoea, meningitis, pneumonia, sexual transmission diseases and nosocomial infections 
are the most severe bacterial infections, which affect millions of people worldwide. Moreover, the indiscriminate use 
of antibiotic drugs in the last decades has triggered an increasing multiple resistance towards these drugs, which 
represent a serious global socioeconomic and public health risk. It is estimated that 33,000 and 35,000 people die 
yearly in Europe and the United States, respectively, as a direct result of antimicrobial resistance. For all these reasons, 
there is an emerging need to find novel alternatives to overcome these issues and reduced the morbidity and mortal‑
ity associated to bacterial infectious diseases. In that sense, nanotechnological approaches, especially smart polymeric 
nanoparticles, has wrought a revolution in this field, providing an innovative therapeutic alternative able to improve 
the limitations encountered in available treatments and capable to be effective by theirselves. In this review, we 
examine the current status of most dangerous human infections, together with an in‑depth discussion of the role of 
nanomedicine to overcome the current disadvantages, and specifically the most recent and innovative studies involv‑
ing polymeric nanoparticles against most common bacterial infections of the human body.
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Highlights
• Infectious diseases kill over 17 million people a 
year, and pose a huge health and socioeconomic 
burden worldwide.
• Tuberculosis, diarrhoea, meningitis, pneumonia, 
sexual transmission diseases and nosocomial infec-
tions are the most severe bacterial infections, which 
affect millions of people worldwide.
• Antibiotic multiple resistance is exponentially increas-
ing due to the indiscriminate use of antibiotic drugs.
• It is estimated that 33,000 and 35,000 people die 
yearly in Europe and the United States, respectively, 
as a direct result of antimicrobial resistance.
• Nanotechnological strategies have emerged in the 
recent years as a promising alternative to solve 
these problems and improve available antibiotics 
effectiveness.
• It is well reported that polymers possess by them-
selves antibiotic effect.
• State-of-the-art polymeric nanoparticles possess 
optimal physicochemical characteristics to become 
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Introduction
Infectious diseases kill over 17 million people a year over 
the world [1]. Bacterial infections have a large impact on 
public health. Drug-resistant bacteria, viruses, parasites 
and fungi cause 700,000 deaths every year worldwide [2]. 
The latest Global Health Study undertaken by the World 
Health Organization (WHO) dated from 2016, estimated 
that infectious and parasitic diseases represent 9.7% from 
the whole deaths worldwide. In this ranking, tubercu-
losis has been placed as the first cause of death among 
bacterial infections (2.3% of global deaths), followed by 
diarrhoeal bacterial diseases (2%), meningitis (0.5%), bac-
terial sexual transmission disease (syphilis, chlamydia 
and gonorrhoea, 0.2%) and encephalitis (0.2%) [1]. Simi-
larly, the latest reports of the Global Burden of Diseases 
consortium highlighted that, in 2016, infectious diar-
rhoea was the eighth leading cause of death among all 
ages and the fifth leading cause of death among children, 
being Shigella and enterotoxigenic Escherichia coli the 
most frequent and mortal bacteria [3, 4]; incident cases 
of meningitis globally increased 2.82 million in 2016, 
being the Pneumococcus the largest cause of years of life 
lived with disability (YLDs) [5]; the number of tuberculo-
sis deaths was 1.21 million among HIV-negative individ-
uals and 0.24 million among HIV-positive individuals [6]. 
Furthermore, in 2017, 11.0 million sepsis-related deaths 
were reported worldwide [7].
Not surprisingly, these data are significantly higher 
than the global computation in developing countries, 
since the lack of universal health systems, public health 
problems and access to potable drinking water, together 
with the limited financial resources, aggravate the situ-
ation of these patients [1, 4]. On the other hand, the 
indiscriminate use of antibiotic drugs in recent decades 
worldwide has generated a global public health problem 
due to the emergence of multiple resistance against anti-
biotics by a high number of microorganisms [8]. It is pre-
dicted that, by 2050, multidrug resistant (MDR) bacteria 
will cause up to 10 million deaths annually, with a burden 
cost in the global economy reaching US$100 trillion [2].
Although the human body lives together with its own 
microbiota in an advantageous symbiosis, there are many 
bacteria pathogens capable to infect and colonize the 
human body and cause serious diseases (Table  1). Bac-
teria can be transmitted to humans through food, water, 
air, or living vectors. All of the human organs are sus-
ceptible to be infected by bacteria, but each species has 
a predilection for certain organs, and some organs are 
more sensitive to suffer bacterial infection (Fig.  1) [9]. 
"ESKAPE" bacteria is one of the groups of bacteria that 
are of greatest concern in the health environment due 
to several reasons. ESKAPE is an acronym encompass-
ing the names of six most dangerous bacterial human 
pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseu-
domonas aeruginosa, and Enterobacter species) com-
monly associated with a high antimicrobial resistance, 
which are responsible of the majority of nosocomial 
infections. Curiously, this acronym also references to the 
ability of these microorganism to escape the effects of 
commonly used antibiotics through evolutionarily devel-
oped mechanisms [10].
Other of the most dangerous bacteria for humans are 
Neisseria meningitides and Vibrio cholera, both belong-
ing to the proteobacteria phylum N. meningitides is an 
exclusively human pathogen, causing bacterial menin-
gitis in children and young adults, which finally lead to 
the death of the ten percent of the cases [11]. People 
with confirmed N. meningitidis infection should be hos-
pitalized immediately for antibiotic treatment due to the 
severity of the symptoms [12]. On its behalf, V. cholerae 
causes cholera in humans. This pathogen is usually trans-
mitted through the ingestion of contaminated food or 
water [13]. V. cholerae infection is limited to the intestinal 
tract, where disease symptoms are primarily caused by its 
toxins. It is mostly found in developing countries, since 
the lack of access to drinking water promotes its expan-
sion, becoming an endemic disease in these regions [14].
Clostridium difficile is the most important cause of 
pseudomembranous colitis, an infection of the colon, 
often secondary to the eradication of the saprophyte 
microbiota. Antibiotics, especially broad-spectrum anti-
biotics, cause an imbalance of the intestinal flora, lead-
ing to an overpopulation of C. difficile, which in turn 
promotes the pseudomembranous colitis [15]. Due to 
the severity of this infection, monoclonal antibodies and 
drugs such Surotomycin, Rifamixin or Cadazolid are 
being studied in clinical trials as promising alternatives to 
currently available treatments [16].
Mycobacterium tuberculosis is responsible for the larg-
est number of tuberculosis cases and the first cause of 
death in the world due to bacterial infection. Humans 
are the only known reservoirs of M. tuberculosis, which 
causes severe infection in lungs, but also spreading to 
other organs [17]. Importantly, the unusual structure 
and chemical composition of the mycobacterial cell wall 
deeply difficult the efficacy of the treatments, since drug 
penetration is almost impossible. [18].
Finally, Chlamydia trachomatis is an obligate intra-
cellular bacterium that can replicate only within a host 
human cell [19]. C. trachomatis causes trachoma, ocu-
logenital infections, nongonococcal urethritis and pneu-
monia. Moreover, C. trachomatis is the most common 
infectious cause of blindness and the most common sex-
ually transmitted bacterium [20].
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Table 1 Characteristics of most dangerous human infectious bacteria
Bacteria specie Phylum Order Gram ± Medium Disease Treatment Morphology
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All these facts together highlight the global importance 
and severity of the antibiotic resistance issue, which 
arises the need to find new alternatives for these patients. 
In this sense, nanomedicine has become in the last dec-
ades in a revolutionary therapeutic tool [21]. The ability 
of controlled drug delivery systems to carry inside differ-
ent antibiotics, enhance their solubility, target them to a 
specific organ and improve its penetration has opened a 
window of opportunities to overcome the disadvantages 
of the current antibiotic treatments and novel potential 
molecules [21]. Moreover, the possibility of accumulate 
the drug at the site of infection for a longer time, as well 
as avoiding the escape mechanisms of bacteria generate a 
great interest among the scientific community [21].
Specifically, polymeric nanoparticles (NPs) have 
emerged as a promising alternative mainly due to the 
polymeric structure. Polymeric materials have exhibited 
to possess antibiotic effects [22]. Among their several 
effects, it is highlighted their ability to accumulate onto 
the cell membranes, which finally promote the destruc-
tion of the entire bacteria cell. These polymer effects 
together with antibacterial properties of loaded drugs 
Table 1 (continued)
*Commonly aerobic/less common facultative anaerobic
¥ Facultative anaerobic
Fig. 1 Most common human bacterial infections
Bacteria specie Phylum Order Gram ± Medium Disease Treatment Morphology
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confers to these nanosystems many advantages as a mul-
titarget approach against different infections [22]. Thus, 
in this review we deeply investigate and describe the 
main advantages of nanomedicine, specifically the state-
of-the-art polymeric NPs, against most common human 
bacterial infections, as well as recent advances in novel 
drugs-loaded polymeric NPs as antibiotic therapies.
Nanoparticles to improve antibacterial therapies
In the 1940s, penicinils promoted a revolution in the 
therapy of the twentieth century, significantly contribut-
ing to the control of infectious diseases, which were the 
leading cause of human mortality so far [23]. Due to this 
therapeutic success, over the last 50 decades, there was 
an indiscriminate use of these drugs, which led to several 
antibiotic resistances by many bacterial species, which 
implies a serious public health risk. Spontaneous modi-
fications in the genetic material of these microorgan-
isms improved their adaptation to the environment and 
the development of molecular mechanisms that limit the 
action of these agents, such as the production of degrad-
ing enzymes or the increase in their efflux pumps [10]. 
It is estimated that 33,000 and 35,000 people die yearly 
in Europe and the United States, respectively, as a direct 
result of antimicrobial resistance [24, 25].
For these reasons, the is a current need to improve the 
biopharmaceutical properties of existing compounds 
and also to find new, more effective antibacterial agents. 
Recent advances in nanotechnology, particularly the 
design of novel nanoparticles (NPs) as controlled drug 
delivery systems, have supposed a promising alternative 
impact in the general medicine, and specifically in the 
antimicrobial therapy [26]. NPs, controlled drug deliv-
ery systems with a diameter of 1–1000 nm and polymeric 
core, may offer remarkable improvements in the biop-
harmaceutical properties of antibacterial agents. Nota-
bly, they can provide an enhancement of drug solubility, 
modulation of drug release and delivery, promotion of 
stealth for immune evasion, targeting of antibacterial 
molecules to desired organs and tissues and increase the 
retention time in-situ, as well as the simultaneous deliv-
ery of multiple drugs [27]. Such unique advantages allow 
these systems to improve the therapeutic index of drug 
payloads when compared with free drug counterparts, 
perform an efficient focused therapy at the site of infec-
tion, increasing the penetration of loaded molecules 
through the bacteria cell wall, thus opening a window 
against antibacterial resistance [28].
Different strategies by which NPs can improve anti-
bacterial therapy efficacy have already been described 
(Fig. 2) [29, 30]. The most important strategy is the anti-
biotic localization to the pathogen cell. This allows to 
reduce the therapeutic doses of the drugs, maintaining 
their efficacy and reducing the adverse effects [26]. The 
modulation of drug-pathogen interaction to overcome 
antibiotic resistance is another of the most effective strat-
egies. For example, liposomes have the capacity of fusing 
themselves directly with bacterial membranes. This leads 
to a burst-release of high dose of loaded antibiotics into 
the bacteria, overwhelming the efflux pumps and over-
coming this bacterial resistance mechanism [26]. NPs 
enable free drug “anti-virulence” therapy. In comparison 
to traditional antibiotics, nanoparticles are less likely to 
develop drug resistance, since there is no bactericidal 
effect, but rather promoted physical and non-specific 
structural disruption of bacterial membranes, that ulti-
mately led to an increased permeation and bacterial cell 
death. This process is less likely to elicit resistance devel-
opment [31]. Furthermore, some anti-virulence platforms 
include monoclonal antibodies, anti-sera, small-molecule 
inhibitors or small polymers [26].
Nanoparticles for bacteria recognition
The recognition of bacteria by detecting specific ele-
ments with NPs, which would act as biosensors, is one 
of the most innovative and emerging strategies to rapidly 
recognise and treat an infection. The large surface area of 
nanoparticles allows, not only the increase of the contact 
between loaded drug and bacterial film, but also a more 
efficient recruiting of bacterial antigens. Thus, different 
strategies have been explored in that sense.
Antibody‑based strategies
NPs surface modification with specific antibodies 
comprises the most commonly used bio-recognition 
approach to capture pathogens cells due to their versatil-
ity and their high affinity to different bacteria elements. 
Polyclonal, monoclonal, and engineered antibody frag-
ments are the antibodies employed in immunology-based 
assays in bacterial infections [32].
Aptamer‑based strategies
Aptamers are single stranded nucleic acids which offer 
many advantages over antibody-based strategies. These 
advantages include their chemical stability, low-cost, 
and large-scale synthesis process. Moreover, due to 
their small size (between 3 and 5 nm), aptamers exhibit 
a remarkable binding affinity against different bacterial 
cell elements, thus resulting in a significant reduction of 
the detection limit [32]. Systematic Evolution of Ligands 
by Exponential enrichment (SELEX) technique is com-
monly used in the design of aptamers for a huge variety 
of bacteria [33]. This technique is based on the identifica-
tion and amplification of an effective aptamer sequence, 
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which will be conjugated with -COOH –SH and -NH2 
groups and immobilize onto NPs surface.
Electrostatic interaction‑based strategies
Positively charged nanoparticles can bind to negatively 
charged protein surfaces, such bacteria cell mem-
brane, through electrostatic interactions. Several type 
of nanoparticles, such as chitosan nanoparticles, gold 
nanoparticles, graphene oxide nanoparticles or carbon 
nanotubes, have been reported to interact with bacte-
ria elements, such enzymes, and inhibiting their activi-
ties. Moreover, due to the reversible characteristic of 
electrostatic interactions, this recognition’s process 
can be used as an indirect indicator of bacterial cell 
concentration [32].
Bacteriophage‑based strategies
Bacteriophages are basic bacteria-infecting viruses com-
prised by a protein capsid evolving of nucleic acids and 
tail fibres. These tail fibres are used as recognition ele-
ments, which can specifically bind to bacterial surface 
receptors. The most important characteristic of bacterio-
phages is their ability to distinguish inactive versus viable 
host cells, since they can only replicate within alive bacte-
rial cells [34]. In addition, their synthesis and purification 
processes are relatively easy and inexpensive, together 
with their medium size (ca. 100  nm), making them a 
promising biosensoring platform to be combined with 
NPs for bacteria detection [32].
Nanoparticles to protect and improve drug effectiveness
The targeting and recognition of specific bacterial struc-
tures is not the only strategy to improve antibacterial 
therapies using nanotechnology. The encapsulation of 
available antibiotics to improve their properties, as well 
as new molecules with bactericidal potential, is one of the 
main objectives of NPs. Likewise, the preservation of the 
physicochemical properties of encapsulated compounds, 
as well as an increase in their stability throughout their 
storage and administration in  vivo, are fundamental 
characteristics provided by nanocarriers that provide a 
guarantee of success in therapies.
Nitric oxide (NO) is one of the compounds that as 
raised much interest in the last years because of its anti-
bacterial properties. NO has been recently identified as 
a key regulator of bacterial biofilm dispersion, but its 
reduced water solubility, short half-life and extremely 
reactiveness involve a challenge to exploit its therapeutic 
potential [35]. In that sense, Duong et al. developed two 
different NO-loaded controlled drug delivery systems: (i) 
functional gold NPs and (ii) core cross-linked star poly-
mers to improve the stability of NO during the storage 
and perform a controlled release [36, 37]. Both systems 
were exposed to Pseudomonas biofilms and NO disper-
sant activity was evaluated. In both cases, nanosystems 
increased NO stability, showed a slow and controlled 
delivery of NO, and exhibited a great efficacy in prevent-
ing both cell attachment and biofilm formation, with no 
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Fig. 2 Main improvements brought by nanoparticles for the antibacterial therapy
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Similarly, another interesting study explored the 
co-encapsulation of NO and gentamicin in poly-
oligo(ethyleneglycol) methyl ether methacrylate NPs as a 
potential antibacterial tool against bacterial biofilm and 
planktonic cultures [38]. Gentamicin is an aminogluco-
side widely used in several bacterial infections, but with 
serious ear and kidney toxicity. In this study, authors 
founded that developed NPs were able to perform a con-
trolled release both agents simultaneously, and exhibited 
synergistic effects. The viability of planktonic cultures 
and Pseudomonas biofilm was reduced by more than 
95% and 90%, respectively, whereas free drugs treatments 
alone resulted in less than 20% of decrease in biofilm 
viability.
Another antibacterial strategy exploited with nano-
technology is the increase of the temperature in the 
infected area. It has been described that this increase can 
induce a detachment of bacteria biofilms and reduction 
of biofilm biomass. In that sense, Nguyen et al. developed 
iron oxide NPs to disrupt the bacterial biofilm through a 
NPs-mediated hyperthermia [39]. Upon an exposure to a 
magnetic field, developed NPs induced the detachment 
of biofilm cells and reduced by 2-log the number of col-
ony forming units (CFUs) in both biofilm and planktonic 
phases in combination with gentamicin treatment.
All these findings together may find broad applications 
across a range of clinical and industrial settings related to 
bacterial infections management.
Polymers as a new generation of antibacterial 
agents
In the last decade, mainly due to the rise of antibacterial 
drugs resistance, there has been an increase in the search 
of new compounds able to act against these microorgan-
isms. In this context, antimicrobial polymers (AMP) have 
emerged as a promising alternative in this field [40]. As 
described above, polymers by themselves have shown to 
be promising therapeutic agents against multiple antibi-
otic resistant bacteria. These materials were designed to 
mimic the chemical structure of antimicrobial peptides, 
which are part of the human immune system and are 
responsible of the protection of the host against differ-
ent pathogen [41]. Hydrophobicity and cationic charge 
have been described as the most important properties 
of these materials to possess antibacterial activity. These 
characteristics lead to an accumulation of these polymers 
onto the cell membranes, creating pores on the bacterial 
structure, thus finally killing them [42].
The composition and distribution of the monomers in 
the polymer chain have been also described to possess 
a significant impact in the antibacterial activity. Some 
studies have pointed out that the incorporation of hydro-
phobic and amine groups in the terminal positions of the 
polymer chain allows to vary its hydrophobicity and lead 
to adjust the extent of bacterium membrane disruption, 
which in turn governs the antimicrobial activity [43, 44]. 
Furthermore, it has been also described that the incorpo-
ration of oligoethylene glycol in the polymeric structure 
prevent the complexation of AMP with proteins, which 
significantly contributes to maintain antimicrobial effi-
cacy [44]. Likewise, polymer architecture also influences 
in its bactericidal effect. It has been described that poly-
mer longer chains are more bacteriostatic against Gram-
negative bacteria, whereas polymer shorter chains have 
less haemocompatibility. Moreover, hyperbranched poly-
meric structures possess similar antimicrobial activity 
compared to the short linear random copolymers with no 
hemagglutination [45].
Due to their inhering chemical structure, AMP can 
either promote antibacterial effect or serve as matrix 
to improve the efficacy of loaded antibiotics [22]. Syn-
ergistic effect between AMP and antibiotics have been 
described by several authors. Thus, Namivandi-Zangeneh 
et al. recently developed an antimicrobial platform com-
posed by a potent synthetic AMP (oligoethylene glycol, 
ethylhexyl, and primary amine groups) and two antibiot-
ics, colistin and doxycycline [46]. This study reveals the 
improvement.
of the bacteriostatic efficacy of both AMP and anti-
biotics when administered together. Moreover, this 
synergistic combination reduces the rate of resistance 
development compared to free compounds alone. Simi-
larly, authors recently developed another platform where 
this AMP was combined with essential oils, carvacrol 
and eugenol [47]. Essential oils are natural antimicro-
bial agents produced by many plants. As it was expected, 
co-administration of these compounds significantly 
improves the efficacy against P. aeruginosa biofilms com-
pared to free compounds. In this case, the synergistic 
bactericidal activity was attributed to the targeted deliv-
ery of carvacrol and eugenol, driven by the electrostatic 
interaction between positively polymer and negatively 
charged bacteria.
Ultimately, the versatility in the design of polymers has 
allowed to exploit all these advantages and obtain differ-
ent polymeric structures with antimicrobial activity.
Polymers mimicking natural peptides
Natural peptides are commonly produced as an innate 
immune response against bacterial infections [22, 48]. 
The mechanism of action use to be non-receptor depend-
ent and use to involve an interruption of internal cellu-
lar function [49, 50]. However, the clinical application 
of these peptides possesses several limitations because 
of their potential toxicity to the host, reduced half-
life caused by protein binding, and susceptibility to 
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degradation by host proteases [22]. To overcome these 
disadvantages, in the last years, a variety of polymers 
have been designed to simulate these natural peptides. 
Thus, many studies have described synthetic AMP mim-
icking peptides against most common human bacteria, 
such S. aureus, E. faecium or P. aeruginosa [22]. These 
synthetic AMP, such brilacidin or idolidicin variants, can 
act as bacteriostatic or bactericidal compounds with a 
reduced toxicity to the host, some of them even reaching 
phase II of clinical trials [51].
Polymers enclosing phosphor‑ and sulfo‑ derivatives
Other option of polymer strategy against bacteria are 
polysulphonium and polyphosphonium. Their mecha-
nism of action is similar to those polymers which enclose 
quaternary ammonium in their structure, inducing a bac-
teria cell wall damage leading to their death [22]. These 
kind of matrices have been restricted to alkyl and aryl 
derivatives, which exhibit both hydrophobic and hydro-
philic domains, a required feature to possess antimicro-
bial activity [52].
Phenol and benzoic derivative polymers
Aromatic compounds, such as benzoic acid or phenol 
group, have been described to possess antimicrobial 
properties, and their incorporation in the synthesis of 
novel polymers grants them the desired antimicrobial 
activity. Their mechanism of action is also related to the 
bacteria cell membrane breakdown, and are commonly 
used as environmental antibacterial agents. Thus, a few 
decades ago, some authors already explored the synthesis 
of vinyl polymers containing benzoic or phenol residues 
as terminal groups to evaluate their effectiveness against 
S. aureus and P. aeruginosa, demonstrating their efficacy 
against this pathogens [53].
Halogen‑derivatives enclosing polymers
Antimicrobial properties of halogens are a well described 
mechanism that has been used in the design of most 
common antimicrobial agents, such chloramphenicol 
or vancomycin (which contain chlorine), or fluoroqui-
nolones (which contains fluorine) [54]. Polymers con-
taining halogens combine the antimicrobial properties 
of both structures, thus leading to an improvement of 
therapeutic efficacy. Some examples of this strategy are 
Quaterfluo®, a polymeric fluorine containing antimi-
crobial surfactants, cationic fluorinated polymer emul-
sions, polymers contain N-halamines, and halogenated 
polymers containing antimicrobials agents, such as cip-
rofloxacin [52, 55–57]. In the latter case, authors dem-
onstrated that the incorporation of ciprofloxacin into the 
polymeric acidic matrix of amorphous solid dispersions, 
such Carbopol or Eudragit L100, improved the solubility 
of ciprofloxacin both in water and in simulated intestinal 
fluid. Moreover, these formulations improve the minimal 
inhibitory concentration of ciprofloxacin in S. aureus, E. 
coli, K. pneumoniae and P. aeruginosa cultures [56].
Amphiphilic antibacterial polymers
It has been demonstrated that polymer structures as well 
as their physicochemical properties, such as their molec-
ular arrangement, molecular weight or ratio of amphi-
philic composition, are the most important determinants 
of these materials which significantly compromise their 
selectivity and antimicrobial potency [22]. The ideal 
amphiphilic antibacterial polymer should possess a low 
molecular weight and low-level of lipophilicity, harbour-
ing a cationic arm to incur adequate antibacterial activity 
with a minimum haemolysis activity towards red blood 
cells [58]. Some studies have demonstrated that AMP-
mimicking polyurethanes, with a lower hydrophobic 
regions and higher cationic strength, show higher bacte-
ricidal effect against E. coli with a lower haemolysis grade 
[59]. Likewise, degradable properties of AMP are instru-
mental for their antibacterial potency. Thus, changes on 
amine functionality and monomer composition of AMP 
to control their degradation rate could enhance the lifes-
pan of the antimicrobial activity [60].
Organometallic polymers
Organometallic polymers are characterized by polymeric 
matrix containing metals bonded to at least one organic 
molecule carbon by coordination bonds, π-bonds or by 
σ-/π-bonds to other elements [22]. One of the most used 
organometallic polymers are the silver-containing poly-
mers, which have a higher antimicrobial activity in their 
solid form and have proven to be effective against most 
common bacterial infections, such P. aeruginosa, E. coli, 
A. niger or S. aureus [52]. Due to the environmental risk 
of metals compounds, the use of this kind of materials 
is compromised. However, a recent study carried out by 
Awad et al. explored the development of an eco-friendly 
silver-polystyrene nanocarrier using an extract of orange 
peel to reduce silver nitrate before creating the polymeric 
matrix [61]. Nevertheless, this kind of material requires 
further investigation to ensure their environmental safety.
Recent polymeric nanoparticles against most 
common human bacterial infections
Polymeric nanoparticles for pulmonary infections
Respiratory infections, specifically lower tract lung infec-
tions, are a leading cause of morbidity and mortality 
worldwide. In 2016, lower respiratory infections (LRI) 
caused 2,377,697 deaths in people of all ages, being the 
adults older than 70 years the cohort of population with 
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a higher risk. Streptococcus pneumoniae was the leading 
cause of LRI morbidity and mortality globally, contribut-
ing to more deaths than all other aetiologies combined 
[62]. According to WHO, pneumonia accounts for 15% 
of all deaths of children under 5  years old, killing 808 
694 children in 2017 over the world [1]. Bacteria related 
to lung infections show a high resistance to antibacterial 
drugs, which has promoted a need to find new alterna-
tives to solve this problem. Nanotechnology has shown 
to be a promising alternative to improve the success of 
therapy in these diseases (Table 2).
Among all bacterial infectious diseases associated 
with P. aeruginosa, lung infections are one of the most 
frequent, commonly as hospital-acquired pneumonia 
[63]. In that sense, an interesting study carried out by 
Schaefers et  al. explored the development of polymeric 
NPs (PNPs) co-encapsulated with PopB, the P. aerugi-
nosa type III secretion system protein, and its chaperon 
protein PcrH as a vaccine against IL-17 secretion by CD4 
helper T cells in acute P. aeruginosa pneumonia [64]. 
This vaccine was administered intranasally in an in vivo 
mouse model. At the end of the study, authors found that 
PNPs-immunized mice exhibit 3–fourfold higher Th17 
responses both in the lung and in the spleen compared 
to those immunized with free PopB/PcrH. Similarly, Dea-
con et  al. explored the potential of PNPs against P. aer-
uginosa lung infections, in this case in comorbidity with 
cystic fibrosis. The aim of this study was the improve-
ment of tobramycin bioavailability by its incorporation 
in PNPs. Tobramycin is an aminoglycoside with a limited 
effectiveness because of its inability to penetrate the thick 
DNA-rich mucus in the lungs, thus leading to low antibi-
otic exposure to resident bacteria. The evaluation of the 
nanocarrier effectiveness was performed in a fly in vivo 
model of P. aeruginosa infection [65]. Obtained results 
demonstrated that PNPs treatment double the survival 
rates, achieving 80%, whereas free drug achieves only 
40%. When PNPs are functionalized with DNase, a sig-
nificant DNA degradation in the mucus layer is observed, 
which is correlated with the enhanced PNPs penetration, 
thus finally leading to an increased anti-pseudomonal 
effect.
Tuberculosis infection is the deadliest disease caused 
by a single infectious agent, M. tuberculosis, ahead of 
malaria and HIV. According to WHO report, there were 
10.4 million tuberculosis cases in 2016 and 1.7 million 
people dead worldwide [1]. Due to the high drug resist-
ance that M. tuberculosis presents and the severity and 
extent of the pathology, a need has arisen to find new 
therapeutic alternatives against this pathogen. To over-
come the limitations encountered in currently avail-
able treatments against M. tuberculosis lung infections, 
Coya et  al. designed mannose functionalized PNPs to 
improve the response of innate immune human cells [66]. 
The ability of PNPs to promote inflammation processes 
could be useful against certain pathogens, but long-term 
inflammatory responses could be detrimental to the host. 
Because of that, authors chose the surface modification 
of PNPs with mannose in order to decrease their pro-
inflammatory properties. Authors found that developed 
PNPs are efficiently internalized by human macrophages 
and profoundly remodel the response of M. tuberculo-
sis-infected ones. Thus, grafting ligands at the surface 
of PNPs may be a promising strategy to modulate cell 
metabolism by immune response route and improve the 
efficacy of loaded molecules. Similarly, a recent study car-
ried out by Malik et al. explored the encapsulation of the 
bivalent H1 antigen, a fusion of M. tuberculosis Ag85B 
and ESAT6 proteins, in PNPs to investigate its role in 
immunomodulation and protection in a mice model of 
M. tuberculosis lung infection [67]. In this case, devel-
oped PNPs are also efficiently internalized by the THP-1 
human macrophages and the immunized mice exhibit 
a significant increase in the production of total serum 
IgGs. Moreover, in protection studies, immunized mice 
display significant reductions in lung and spleen bacterial 
load and prolonged survival.
Chlamydia psittaci infections are commonly trans-
ferred to humans via the inhalation of contaminated 
aerosols originating from excretions from infected ani-
mals. A recent study reported that C. psittaci lung infec-
tion may contribute to increase the risk of co-infection 
with other pathogens, including the flu virus, and has 
highlighted to be a one of the causes of community-
acquired pneumonia [68, 69]. Related to that, Li et  al. 
developed a novel immunization strategy, simultaneous 
intranasal and intramuscular administration of PNPs 
coated with C. psittaci antigens to determine the differ-
ent types of immune response and their protective role in 
an in vivo model of lung infection [70]. Obtained results 
showed that developed PNPs promote a strong immu-
nity response by producing meaningfully high levels of 
IgG and secretory IgA antibodies. In addition, in  vivo 
results exhibited that PNPs vaccine inhibits C. psittaci 
dissemination to different organs, as well as a reduction 
of bacterial loading and the degree of inflammation in the 
infected lungs.
Polymeric nanoparticles for oral cavity infections
Oral cavity infections, mainly caused by bacterium bio-
film formation in different oral structures, involve a 
major public health and economic burdens worldwide. 
Oral biofilms are responsible for causing tooth decay and 
dental caries, and present a high prevalence in humans 
(> 90% of adult population and (> 30% of schoolchildren 
over the world) [71]. Just in U.S., annual expenditures 
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related to oral cavity infections interventions exceed 
$120 billion [72]. In addition, drug retention in the oral 
cavity remains a major challenge, thus limiting the clini-
cal practice incorporation of many anti-biofilms active 
compounds [73]. All of these reasons have triggered the 
development of various PNPs in recent years to treat oral 
cavity infections (Table 3).
Streptococcus mutans and Candida albicans are 
the two pathogens which are commonly associated to 
aggressive dental caries, most frequently affecting chil-
dren from developing countries [74–76]. Importantly, 
both bacteria interact synergistically in forming dual-
species biofilms, which hardly complicate their treat-
ment. Since chitosan NPs have proven to be effective 
against a broad spectrum of pathogens, Ikono et  al. 
evaluated their effect on dental caries-associated to S. 
mutans and C. albicans biofilms [77]. Obtained results 
showed that PNPs significantly decrease the cell viability 
of both pathogens in a concentration dependent man-
ner. Moreover, although biofilm mass is not reduced 
in the first hours with these PNPs, a greater inhibition 
of biofilm growing is observed at 18 h of chitosan NPs 
incubation in the site of action. Similarly, Sims and col-
leges explored the potential of PNPs as a therapeutic 
tool against S. mutans oral biofilms. In this case, authors 
developed two novel pH-responsive PNPs containing 
farnesol (a hydrophobic antibacterial drug) and thonzo-
nium bromide (a highly potent, FDA-approved antibac-
terial drug), respectively [78]. In this case, authors found 
that both developed PNPs markedly amplify the anti-
biofilm activity of loaded molecules, showing reductions 
of ~ 2 to 6 log CFUs. Furthermore, farnesol-loaded PNPs 
are able to reduce total biomass by disrupting insoluble 
glucan formation. All these findings open a new win-
dow for the local treatment of dental caries caused by S. 
mutans biofilms.
Another interesting study related to oral biofilms was 
performed by Liu et  al. who developed micellar PNPs 
which possess pH adaptivity to self-target to the acidic 
environment of bacteria biofilm. This carrier was com-
posed by a PEGylated poly(β-amino esters) matrix, sur-
face conjugated with triclosan, a potent bactericidal and 
fungicidal agent. Its effectiveness was evaluated both in 
in vitro and in vivo models of MDR S. aureus and E. coli 
oral biofilms[79]. In vitro results showed that PEG-PAE-
triclosan are more efficient in killing MDR S. aureus, 
E. coli and oral streptococcal biofilms than free triclosan. 
Furthermore, in  vivo assays showed that these PNPs 
also yield better eradication efficacy towards a MDR S. 
aureus-infection compared to free triclosan, exhibiting a 
bacterial killing at 30–40 fold lower triclosan-equivalent 
concentrations than achieved by triclosan in solution in 
the ex vivo analysis.
Mahmoud et  al. also explored the potential of PNPs 
in the therapeutic approach of bacterial oral infections, 
in this case of Porphyromonas gingivalis, one of the 
most common periodontal pathogens in humans [80]. It 
has been shown that the interaction between commen-
sal streptococci and P.gingivalis significantly promotes 
the colonization of the oral cavity by P. gingivalis. This 
study describes the development of PLGA NPs surface-
modified with BAR, a peptide derived from Streptococ-
cus gordonii, which has previously shown to effectively 
inhibit the adherence of P. gingivalis to streptococci, thus 
reducing P. gingivalis periodontitis. Since BAR is mainly 
effective when biofilm is not yet established, the aim of 
this work was to improve the effect of BAR by PNPs tar-
geting and bioaccumulation, to significantly disrupt an 
already established P. gingivalis /S. gordonii biofilm [81]. 
Obtained results showed that developed nanocarrier sig-
nificantly improve bone loss and IL-17 expression (ana-
lysed parameters of periodontal infection) of infected 
animals. Moreover, PNPs shown to be safe for gingi-
val keratinocytes and red blood cells both in  vitro and 
in  vivo. Thus, this therapeutic alternative highlights the 
potential of PNPs as a biocompatible platform for local 
translatable oral biofilm applications.
Similarly, Toledano-Osorio et  al. developed three dif-
ferent PNPs loading respectively zinc (Zn), calcium (Ca) 
and doxycycline, and evaluated their efficacy against 
several bacteria involved in oral infections, such P. gingi-
valis, S. gordonii or S. mutans, among others[82]. Authors 
demonstrated that developed PNPs are able to reduce the 
bacterial viability, been the doxycycline PNPs the most 
effective, reducing viability almost up to 99%, followed 
by Ca PNPs and Zn PNPs. Furthermore, they also found 
that the most PNPs-susceptible bacteria are P. gingivalis, 
S. mutans and L. lactis, and being S. gordonii and S. sobri-
nus the most resistant.
Polymeric nanoparticles for gastrointestinal tract 
infections
Causes of gastrointestinal infections include viral, bac-
terial, parasitic and fungal pathogens. They vary among 
different geographical regions, and are compromised 
by co-morbidities and host immune status [1]. Bacte-
ria are responsible for 20–40% of diarrhoeal episodes 
worldwide, thus contributing to high rates of childhood 
mortality in developing regions, and substantial morbid-
ity and economic losses in developed regions [83]. Due 
to the severity of these diseases, many authors are been 
recently analysing the potential of PNPs to improve the 
pharmacological properties of existing antibiotics and/or 
to explore novel therapeutic alternatives (Table 4).
As explained above, V. cholerae is the bacterium that 
causes cholera in humans and the most common cause 
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of bacterial diarrhoea worldwide [14]. As happens with 
other bacterial infections, the appearance of MDR has 
promoted an urgent need to develop alternative treat-
ments against V. cholera. In that sense, Das and colleges 
designed surface modified PLGA NPs with PEG and 
GM1, a key host receptor for choler toxin, as a recruit-
ment and clearance tool of enterotoxin [84]. Obtained 
results demonstrated that these PNPs are able to selec-
tively and stably binding cholera toxin, thus neutraliz-
ing its actions. Moreover, developed PNPs attenuate the 
production and fluid responses of epithelial 3′, 5′-cyclic 
adenosine monophosphate both in in  vitro and in  vivo 
models of V. cholera infection.
Gastroenteritis is one of the most common gastrointes-
tinal disorders in humans, and is caused by a few patho-
gens, among which C. jejuni stands out. Farm chickens 
are an important reservoir of C. jejuni and although it 
does not cause clinical symptoms in these animals, it 
can be transmitted to humans by consumption of under-
cooked poultry chicken meat contaminated by intestinal 
contents. Reducing the C. jejuni colonization of gastroin-
testinal tract of farm chickens would lead to a reduction 
of incidence of human gastroenteritis. Related to that, 
Taha-Abdelaziz et  al. developed PNPs containing CpG 
oligodeoxynucleotide (ODNs), a short synthetic DNA 
sequence highly prevalent in bacterial DNA, in order to 
evaluate their potential effectiveness in reducing C. jejuni 
burden in chickens [85]. ODNs have shown to bind to 
and activate Toll-like receptor 9, which initiate an innate 
immune response that subsequently promotes the devel-
opment of an adaptive immunity against the bacteria 
to which originally belong [86]. The authors found that 
developed PNPs are able to reduce the intestinal burden 
of C. jejuni in chickens, protect the intestinal epithelium 
and improve systemic immune responses of these ani-
mals. The administration of these PNPs together with C. 
jejuni lysate enhances the proliferation of specific micro-
bial groups that reduce the colonization of C. jejuni.
Another bacteria pathogen associated with gastroen-
teritis and diarrhoea disorders is Salmonella spp., which 
has become a major public health problem worldwide 
[87, 88]. MDR issues also compromise antibiotic treat-
ment of Salmonella infections, thus efforts in identifying 
an alternative therapeutic approach against Salmonella 
are gaining much interest. Cryptdins, Paneth cell pep-
tides, have been reported to own bactericidal activity 
against several intestinal pathogens. To improve their 
pharmacological properties, Rishi and colleges developed 
cryptdin-loaded chitosan NPs to test their effect in a mice 
model of Salmonella typhimurium gastrointestinal infec-
tion [89]. Developed PNPs significantly increase the sur-
vival ratio of treated mice, whereas 100% mortality was 
observed with the free peptide treatment. Furthermore, 
cryptdin-loaded PNPs are able to decrease the levels of 
oxidant molecules, increase the level of antioxidants ones, 
thus all together has been the first pre-clinical report of 
cryptdin effectiveness by its suitable encapsulation.
Helicobacter pylori is a gram-negative, helical bacillus-
shaped bacterium that lives in the human stomach exclu-
sively. Although, infected individuals may never have any 
symptoms, H. pylori infection can produce inflamma-
tion of the gastric mucosa that can progress leading to 
gastritis, peptic ulcer, and mucosa-associated lymphoid 
tissue lymphoma, thus posing a significant healthcare 
burden worldwide [90]. Related to that, Angsantikul et al. 
recently developed clarithromycin-loaded PLGA surface 
modified NPs with PEG and molecules of plasma mem-
branes of gastric epithelial cells [91]. Nowadays, triple 
therapy based on a combination of clarithromycin, pro-
ton pump inhibitor and an antibiotic, such metronida-
zole or amoxicillin, is recommended for the treatment of 
H. pylori infection, but its recent mutations and subse-
quent drug resistance significantly compromised the suc-
cess of this therapeutic option [92]. In this study, authors 
found that, as it was expected, developed PNPs mostly 
accumulate on the bacterial surface in an in vitro model 
of H. pylori. Moreover, surface modified-PNPs exhibit a 
higher therapeutic efficacy in mouse model of H. pylori 
infection, when compared with the free clarithromycin 
and to the non-targeted PNPs. Overall, these results illus-
trate the potential of using natural host cell molecules to 
functionalize PNPs for targeting and delivering of antibi-
otics against pathogens that colonize on that host cells.
Finally, to analysed the biodistribution of PNPs in an 
in vivo infection model, an innovative study carried out 
by Lovmo et  al. evaluated the absorption and interac-
tions of PLGA NPs with epithelial cells and the mucosal 
immune system of a zebrafish in  vivo model of Myco-
bacterium marinum infection, an opportunistic bacteria 
in humans [93]. By fluorescence imaging, authors found 
that PNPs, as well as bacteria, are rapidly taken up in the 
intestine and mainly transported to the spleen and liver. 
Furthermore, in these organs, both PNPs and M. mari-
num bacteria cells are largely localized to leukocytes, pre-
sumably macrophages.
Polymeric nanoparticles for skin infections
Bacterial skin infections e.g. folliculitis, impetigo, furun-
culosis, and wound infections, among others, are the 
most common type of skin infections [94]. Recent stud-
ies have explored the potential of PNPs as a promising 
therapeutic alternative for skin infections (Table 5). The 
major problem resulting from wound infections caused 
by MRSA is the colonization of other organs, which lead 
to an invasive and deep infection, resulting in systemic 
bacteraemia and significant morbidity and mortality. 
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Related to this, Hasan et al. developed mixed PNPs based 
on PLGA/PEI with loaded clindamycin, a semisynthetic 
antibiotic, derived from lincomycin, effective against 
aerobic gram-positive cocci and anaerobic gram-negative 
bacilli. The developed nanocarrier was tested in a MRSA 
culture and ICR mice model of cutaneous wound infec-
tion [95]. Authors found that developed PNPs are able to 
efficiently bind to the MRSA surface, thus enhancing the 
bactericidal activity of clindamycin. Moreover, clindamy-
cin-loaded PNPs significantly accelerate the healing and 
re-epithelialization of wounds in the in vivo assay, with-
out compromising the healthy fibroblast cells activity.
Another pathogen found in chronic wound infections, 
as well as burn wound infections, is P. aeruginosa. Han 
et  al. developed enzyme-encapsulated PLGA NPs and 
evaluated their effectiveness against biofilms formed by 
P. aeruginosa PAO1 [96]. Selected enzyme was pyruvate 
dehydrogenase, since it has been previously described 
that P. aeruginosa biofilm are reverted to an antibiotic-
susceptible state via pyruvate-depletion induced disper-
sion [97]. Obtained results showed that developed PNPs 
extended the activity of this enzyme, thus leading to the 
dispersion of preformed biofilms.
Staphylococcus epidermidis, a common microbiota 
of human body, can originate opportunistic infections 
associated with indwelling medical devices. It shows a 
strong MDR activity, which promotes the need to find 
new pharmacological alternatives. In this context, Ong 
and colleges designed chitosan NPs carrying malasyan 
propolis to evaluate their efficacy against this opportun-
istic pathogen [98]. Malaysian propolis, obtained from 
beehives, is a natural product that exhibits significant 
antimicrobial activity. Authors found that developed 
PNPs are able to effectively disrupt S. epidermidis biofilm 
formation and decrease the bacteria viability to ~ 25%. 
Moreover, propolis-loaded PNPs downregulate genes 
involved in intercellular bacteria adhesion, and exhibit 
a synergism with ciprofloxacin, rifampicin, doxycycline 
and vancomycin. Thus, combination therapy represents 
a way of tackling antibiotic resistance in S. epidermidis 
infections. Similarly, Takahashi et al. evaluated the poten-
tial of PNPs as a novel tool against S. epidermis biofilm 
skin infections. In this case, polymeric matrix was com-
posed by PLGA, and imidazolium cations were loaded 
as active compound [99]. These molecules present some 
advantages, such as good biocompatibility, high perme-
ability to bacteria cell wall, and significant antimicrobial 
activity. Thus, by using a LIVE/DEAD BacLight bacterial 
viability kit, authors demonstrated that developed PNPs 
possess a high antibacterial activity to the bacterial cells 
forming the biofilm, establishing a suitable drug delivery 
system to enhance the potential of polymeric nanocarri-
ers for treating biofilm infections.
Polymeric nanoparticles for urinary tract infections
Urinary tract infections are the most common outpatient 
infections, with a lifetime incidence of 50 − 60% in adult 
women [100]. The prevalence of urinary infection is 0.7% 
worldwide, being the age, sexual activity and diabetes the 
main risk factors. The most common pathogen is Escheri-
chia coli. Importantly, resistance rates of most common 
antibiotic drugs of urinary tract are increasing over the 
years, and are significantly governed by geographical 
location [101]. For these reasons, in the last years, several 
nanotechnological platforms have been exploited for the 
treatment of urinary tract infections (Table 6).
E. coli is a gram-negative bacillus bacterium that is part 
of the normal microbiota of the gastrointestinal tract in 
humans. However, different strains have been shown to 
acquire genetic mutations that are related to virulence 
factors [102]. These strains have been associated with 
gastrointestinal, urinary tract, blood or nervous sys-
tem infections. The high morbidity, as well as the vari-
ety in syndromes and clinical symptoms associated with 
E. coli infections, make this bacterium one of the most 
versatile pathogens of great relevance to humans [103]. 
Several studies have evaluated the potential of PNPs as 
therapeutic tool against E. coli urinary tract infections. 
Related to this, Ashmore and colleges compared the anti-
bacterial efficacy of polymer-coated silver NPs with the 
non-coated ones [104]. The coating of silver NPs with 
polymer significantly improves the antibacterial effi-
cacy of the particles. In addition, polymer-coated silver 
NPs also promote a downregulation of the expression of 
genes associated with the citric acid cycle and amino acid 
metabolism, which are involved in the cellular growth of 
E coli. Similarly, Alfaro-Viquez et  al. developed proan-
thocyanidin-chitosan NPs against bacterial coloniza-
tion of gut epithelial cells by extra-intestinal pathogenic 
E.  coli (ExPEC) [105]. ExPEC are the primary cause of 
urinary tract infections, of which 20% to 45% have shown 
resistance to antibiotics [102]. Cranberry proanthocya-
nidins have widely shown to be effective in the treatment 
of acute cystitis, which indicate that could be a potential 
alternative as antimicrobial therapy of ExPEC infections. 
However, the antioxidant properties of these compounds 
make them very susceptible to degradation, thus reduc-
ing their pharmacological effectiveness. This study 
revealed that developed PNPs protect proanthocyani-
dins from oxidation and decrease the ability of ExPEC to 
invade epithelial cells in a dose-dependent manner.
Co-infections commonly occur in urinary tract. There 
is a wide variety of bacteria that can colonize human 
urinary tract and also related medical devices (e.g. cath-
eters or ureteral stents). Kumar et al. explored the surface 
immobilization of kanamycin-loaded PNPs to prevent 
the bacterial biofilm formation in urethral stents [106]. 
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Kanamycin is an aminoglycoside antibiotic used to treat 
Gram-negative and some Gram-positive bacterial infec-
tions. Recently, is has been shown that combination of 
antibiotics with chitosan matrices significantly improve 
the antibacterial activity of these molecules and reduce 
the resistance of several bacteria [107]. In this study, 
authors reported that, after a covalent immobilization of 
developed kanamycin-loaded PNPs onto the surface of 
an urethral stent, it is observed a significant reduction of 
E. coli and P. mirabilis activity, the selected bacteria. Sim-
ilarly, an interesting work developed by Liu et al. explored 
a therapeutic alternative for urinary co-infections of E. 
coli and S. aureous, which involved the combination of 
antimicrobial photodynamic therapy together with PNPs 
[108]. The technique was based on the photostimulation 
of Chlorin e6 encapsulated charge-conversion PNPs by a 
laser irradiation, which generates the production of reac-
tive oxygen species (ROS) and subsequently killing of 
pathogenic bacteria under an acidic environment. This 
innovative technique was evaluated in both in vitro and 
in  vivo models. Obtained results showed that PNPs are 
able to better recognise Gram-positive (S. aureus) and 
Gram-negative (E. coli) bacteria due to the charge inter-
action, together with a significant in  vitro antibacterial 
efficacy and reduced cytotoxicity. Moreover, in a mouse 
acute cystitis model, authors found a significant decline 
in bacterial cells counts in the urine of NPs-treated ani-
mals compared to those treated with free drug, as well as 
in the bladder tissue after sacrifice.
Another interesting study carried out by Bracic et  al. 
explored the immobilization of PNPs composed by hya-
luronic acid and a lysine-derived biocompatible cationic 
surfactant in silicone catheters to evaluate their effi-
cacy against five different colonizing bacteria of urinary 
tract medical devices [109]. In this case, obtained results 
revealed that that the microbial growth is hampered 
almost by 85% compared to unmodified silicone cath-
eters. Taking a step further, Dayyoub et  al. developed 
silver NPs coated with PLGA carrying norfloxacin, a 
broad-spectrum synthetic antibiotic almost exclusively 
indicated in the treatment of urinary tract infections 
[110]. These PNPs were used to coat polyurethane and 
silicon sheets. This coating prevents the bacterial adhe-
sion of artificial urine and an in vitro encrustation model 
for at least 2 weeks.
P. aeruginosa and K. pneumoniae are not only coloniz-
ers of the respiratory tract, but also of the urinary tract. 
Related to that, Maruthupandy et  al. recently devel-
oped graphene/chitosan NPs against P. aeruginosa and 
K. pneumoniae biofilms [111]. With this study authors 
demonstrated that the viability of both uropathogens is 
reduced almost 95% when incubated with developed 
hybrid NPs.
Polymeric nanoparticles for neuroinfections
Central nervous system (CNS) infections can be caused 
by different agents (e.g. viruses, bacteria, parasites, 
fungi) and, in rare occasions, by prions infections. Men-
ingitis and encephalitis are the most common neuroin-
fections in humans, which involve the inflammation of 
the whole brain of the meninges, the membranes that 
surround the brain and spinal cord, producing a high 
impact on tissue homeostasis [112]. There is a different 
etiological epidemiology of meningitis and encephalitis 
in different geographical regions; pathogens vary across 
different age groups, seasons and geographic loca-
tions. Viruses account for most cases of meningitis and 
encephalitis. Viral meningitis and encephalitis are usu-
ally benign and self-limiting, while bacterial meningitis 
and encephalitis can lead to disastrous damage [113]. 
The cardinal clinical symptoms and signs are mainly 
indistinguishable regardless of the inciting pathogen 
[114].
CNS infections cause significant morbidity and mor-
tality and often require neurosurgical intervention for 
proper diagnosis and treatment. Regarding to WHO, 
Africa had the highest pooled incidence of bacterial 
meningitis (65 cases/100,000 people) [115]. Approxi-
mately 304,000 meningitis patients and 77,000 encepha-
litis patients died all over the world in 2013 comparing to 
46,4000 and 92,000 in 1990 respectively [116].
One of the main limitations during bacterial neuroin-
fections treatment is the inability of  antibiotics  to sur-
pass the  BBB and the blood–cerebrospinal fluid barrier 
(BCSFB), as well as the emerging of antibiotic resistance. 
To this end, drug targeting approaches are being recently 
used to overcome these issues [117]. Getting a local anti-
microbial treatment, the concentration of the drug at the 
site of infection will be improved, as it may modulate 
drug-pathogen interaction to overcome antibiotic resist-
ance, and enabling ’drug-free’ anti-virulence therapy [26]. 
In this context, many studies have been conducted in 
order to improve antibacterial and antivirals compounds 
effectiveness by using of nanotechnology (Table 7).
N. meningitidis is a leading cause of bacterial menin-
gitis and its capsular polysaccharides the basis for sero-
group designation and preventive vaccines [118]. Related 
to that, Gala et al. recently developed a novel meningo-
coccal nanoparticulate vaccine that slowly release those 
antigens, and evaluated the possibly antigen depot effect 
to enhance antigenicity [119]. In order to enhance the 
antigenicity of the vaccine, various adjuvants were evalu-
ated. Results showed that PNPs enhance dendritic cell 
maturation and antigen presentation markers MHC I, 
MHC II, CD40, CD80 and CD86 in this cell line pulsed 
with meningococcal nanoparticulate vaccine. Simi-
larly, Long et  al. developed PNPs to carry amphiphilic 
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lipopolysaccharides, derived from P. aeruginosa to test 
their effectiveness in a mice model of meningitis [120]. P. 
aeruginosa has been shown also to infect the brain and 
spinal cord, and lead to meningitis, brain abscesses, and 
potentially death [121]. Authors found that developed 
PNPs promote a selective recognition of target bacte-
ria and exhibit targeting capacity in  vivo. Moreover, 
this nanocarrier presents a strongly inhibited bacterial 
growth, compared to those controls of the in vitro assays.
The incidence of CNS bacterial infections is associ-
ated with the immunosuppressive drug treatments and 
increased prescription of antibiotics. Immunosuppres-
sion is usually followed by immunodeficiency disease, 
which led to those serious infections and, in case of CNS, 
BBB compromises the cumulative of antibacterial agents. 
In this context, Hong et al. developed a PEGylated-poly-
meric nanocarrier of bacitracin A coated with a specific 
brain-targeting peptide and a P-glycoprotein inhibi-
tor against Pneumococcal meningitis (122). This study 
revealed the enhanced BBB-permeability attributed to 
the synergetic effect of both coating peptides. In  vivo 
results further demonstrated that developed PNPs are 
able to accumulate in brain parenchyma and exhibit high 
therapeutic efficiency with negligible systemic toxicity 
compared to the free drug.
Conclusions
The rise of the number of individuals affected by bacte-
rial infectious diseases constitutes a significant socioec-
onomic health burden worldwide and is mainly related 
to economic and public health problems in develop-
ing countries, and nosocomial infections in developed 
countries. Even when promising therapeutic molecules 
are available, the appearance of MDR events has estab-
lished itself as a serious public health problem world-
wide. The widespread misuse of antibiotic drugs has 
promoted genetic mutations and smart evasion mecha-
nisms by bacteria that have led to an important failure in 
these therapies. As reviewed herein, nanotechnologies 
applied to medicine—nanomedicine—have opened new 
therapeutic opportunities for the treatment of bacterial 
infections. Specifically, state-of-the-art PNPs have dem-
onstrated to possess optimal physicochemical character-
istics to become a therapeutic revolution against human 
bacterial infections. This type of nanocarriers have 
shown to be safe, biodegradable, biocompatible, eas-
ily eliminated and non-toxic for the tissues and organs, 
offer many advantages for currently available molecules. 
Moreover, the targeting to a specific organ, the reduction 
of the adverse effects of many antibiotics, and prolonged 
accumulation over time in the infected area, altogether 
represent a breakthrough in this kind of therapy. Further-
more, polymers themselves have shown to be effective 
against multiple antibiotic resistant bacteria. Thus, the 
combination of loaded drugs together with polymeric 
matrices may offer a synergistic approach with innovative 
outputs and may represent the next step in the treatment 
of bacterial infections.
Research in the next few years will increasingly focus 
on the elucidating and better understanding of the 
molecular mechanisms of bacteria involved in MDR 
events to re-direct the drugs targets. Whilst PNPs are 
undoubtedly among the most efficient tools to over-
come MDR bacteria problems, clinical translation of 
nanoparticles-based treatments remains a challenge for 
the pharmaceutical industry, since nanotechnology has 
not yet entered mainstream clinical practice. Stringent 
protocols of validation of in  vitro and in  vivo proto-
cols are necessary to facilitate translation from bench 
to the clinical trials. Likewise, challenges for large scale 
manufacturing require innovation from chemists and 
engineers and regulatory policies have to be adapted to 
facilitate access to trials and patients. Thus, despite the 
huge progress in preclinical research, the translation of 
these drug delivery systems to clinical practice remains 
one of the most ambitious challenges in this field, and 
will be a major focus of most nanomedicine trials in the 
next decade.
Finally, the social gap between developed and develop-
ing countries, which is closely related to the rise of these 
diseases, is another of the important challenges that we 
face as a society. The development of a global community 
structure that ensures access to antibiotic drugs and their 
correct use, and effective public health measures will rep-
resent an advance against bacterial infections worldwide.
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